donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 03347 Tigermed > Key Indicators
03347 Tigermed
92.600
+2.600+2.89%
YOY
Do not show
Hide blank lines
(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30(Q6)2021/06/30
Per Share IndicaTor
Operating Cash Flow Per Share
32.53% 0.4283 34.14% 1.63 48.64% 1.0022 40.01% 0.5074
Cash Flow Per Share
-18.35% -0.6517 -119.58% -2.1337 -120.12% -2.3423 -857.52% -0.7333
Operating Income Per Share
110.05% 2.5692 68.13% 7.309 55.69% 4.6711 33.55% 2.8326
Net Asset Per Share
16.8% 26.012 15.9% 25.4946 13.37% 23.6419 209.18% 23.5273
Basic Earning Per Share
20.25% 0.7398 55.35% 4.0607 26.17% 2.4608 17.04% 1.7426
Diluted  Earning Per Share
20.25% 0.7398 55.59% 4.0484 26.3% 2.4488 17.1% 1.7306
Profitability
Gross Profit Ratio
-17.25% 38.829% -8.43% 43.121% -3.54% 46.766% -2.2% 47.021%
Operating Profit Ratio
-57.07% 35.997% -0.39% 70.970% 2.43% 68.949% 2.23% 82.910%
Net Profit Ratio
-60.59% 31.574% 2.42% 65.150% 5.56% 64.380% 7.31% 77.524%
Earning Before Tax Ratio
-57.01% 36.087% 1.75% 70.768% 2.43% 68.804% 5.21% 82.559%
ROE
1.95% 2.845% -2.25% 16.997% -17.89% 10.738% -64.06% 7.624%
ROA
-6.15% 2.144% 2.5% 13.488% -14.02% 8.633% -47.7% 6.221%
Yield Quality
Operating Profit To Total Profits
-0.13% 99.753% -2.11% 100.286% -0% 100.211% -2.83% 100.425%
Tax To Total Profits
-173.57% -12.505% 7.1% -7.938% 30.16% -6.429% 23.14% -6.098%
Operating Cash To Total Revenue
-36.91% 16.672% -20.22% 22.302% -4.53% 21.455% 4.84% 17.911%
Capital Structure
Debt Assets Ratio
67.57% 14.635% 56.38% 13.209% 54.94% 10.724% -67.41% 9.302%
Equity Multipler
9.13% 1.3476 8.11% 1.3055 8.5% 1.2777 -30.38% 1.2424
Debt Equity Ratio
79.16% 17.143% 64.97% 15.219% 61.54% 12.013% -74.32% 10.256%
Current Assets To tatal Assets
-25.34% 42.323% -23.44% 45.701% -28.33% 47.630% 31.36% 53.989%
Non Current Assets To Total Assets
33.17% 57.677% 34.72% 54.299% 56.14% 52.370% -21.88% 46.011%
Current Liabilities To tatal Liabilities
8.47% 82.216% 11.26% 76.937% 5.34% 72.699% -10.96% 73.494%
Non Current Liabilities To Total Liabilities
-26.53% 17.784% -25.24% 23.063% -11.89% 27.301% 51.78% 26.506%
Solvency
Current Ratio
-58.93% 3.5175 -56% 4.497 -56.09% 6.1092 352.65% 7.8974
Quick Ratio
-58.94% 3.515 -56.01% 4.4944 -56.11% 6.1057 352.59% 7.8936
Operating Profit To Current Liabilities
-61.08% 0.2193 -23.18% 1.5336 -20.56% 1.3675 118.56% 1.1752
Operrating Cash Flow To Current Liabilities
-42.8% 0.1016 -38.47% 0.4819 -25.96% 0.4255 124.13% 0.2539
Share Equity Without Minority Interest To Total Liabilities
-45.32% 5.0704 -40.85% 5.799 -40.52% 7.2979 340.71% 8.6527
Operating Cash Flow To Total Liabilities
-37.95% 0.0835 -31.55% 0.3708 -22.01% 0.3094 99.58% 0.1866
Operating Profit To Total Liabilities
-57.78% 0.1803 -14.53% 1.1799 -16.33% 0.9942 94.61% 0.8637
Operating Capacity
Current Assets Turnover(T)
119.85% 0.171 9.12% 0.4705 6.18% 0.3089 -55.28% 0.1791
Fixed Assets Turnover(T)
28.26% 3.2159 3.09% 9.5585 9.66% 8.1487 -1.68% 4.4324
Total Assets Turnover(T)
66.19% 0.0752 1.83% 0.2443 -6.1% 0.1646 -40.51% 0.1015
Growth Ability
Operating Revenue GR 3Y
-- 217.813% 61.66% 142.971% -- -- -- --
Gross Income GR 3Y
-- 229.340% 71.87% 142.283% -- -- -- --
Operating Profit GR 3Y
-- 174.687% 18.86% 413.190% -- -- -- --
EBT GR 3Y
-- 203.672% 18.5% 418.276% -- -- -- --
Net Profit GR 3Y
-- 200.687% 10.66% 455.527% -- -- -- --
Net Profit Attributable To The Parent Company GR 3Y
-- 186.423% 7.58% 434.846% -- -- -- --
Total Assets GR 3Y
-- -- 8.81% 453.421% -- -- -- --
Share Equity Without Minority Interest GR 3Y
-- -- 11.89% 587.517% -- -- -- --
Equity GR 3Y
-- -- 12.1% 573.269% -- -- -- --
Total Liabilities GR 3Y
-- -- 66.88% 155.077% -- -- -- --
Basic Earning Per Share GR 3Y
-- 144.080% -0.77% 362.072% -- -- -- --
Other Indicators
Currency Unit
HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Hangzhou Tiger Pharmaceutical Technology Co., Ltd. is a Chinese holding company engaged in providing clinical trial services for new drug research and development. The company operates two branches. The Clinical trial Technical Services Division provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies to help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical trial related Services and Laboratory Services Division is engaged in providing analytical services, such as data management and statistical analysis; logistical and executive support services, such as clinical trial site management; administrative assistance, such as patient recruitment; and consulting services. The division, through its subsidiaries, also provides laboratory services for preclinical and clinical development phases. The company operates in both domestic and overseas markets.
CEO: Xiaoping Ye
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...